Calendario›SNY›InoPro
InoPro
Awareness to Osteopenia's Treatment by Bisphosphonate in Male Suffering From Prostate Cancer
Ensayo de Sanofi en Osteoporosis · Cancer de prostata.
Más ensayos de: Osteoporosis · Cáncer de próstata.
- Fase
- no aplica
- Estado
- Completado
- Participantes
- 180
- Centros
- 1
- Fin del objetivo primario
- jul 2010
previstos
fecha real
Qué significa cada fase y cada estado.
Estudio observacional. Comenzó en ene 2009.
Qué mide
To evaluate the compliance in male patients with prostate cancer treated with Bisphosphonate and that suffered from Osteopenia/osteoporosis. (del registro, en inglés) (6 meses)
Cómo lo describe el promotor
En el documentoEn inglés, del registroPatients with prostate cancer treated in outpatient clinics will be recruited by their urologist physician. Primary Objective: To evaluate the compliance in male patients with prostate cancer treated with Bisphosphonate and that suffered from Osteopenia/osteoporosis. Secondary objectives: To evaluate the compliance of family physicians to prescribe Bisphosphonate for patients upon recommendation by Urologists. To evaluate the overall number of patients treated by Bisphosphonate in the out-patient clinics, To evaluate incidence of osteopenia/osteoporosis in this study population.
Más ensayos de SNY
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Avalglucosidase alfa · Mini-COMET | Fase 2 | En marcha, sin reclutar | sep 2019 (real) |
| Yellow fever vaccine | Fase 2 | En marcha, sin reclutar | may 2022 (real) |
| Yellow fever vaccine · VYF02 | Fase 2 | En marcha, sin reclutar | jun 2022 (real) |
| SAR441344 IV | Fase 2 | En marcha, sin reclutar | sep 2022 (real) |
| Meningococcal Polysaccharide | Fase 3 | En marcha, sin reclutar | mar 2023 (real) |
| Isatuximab IV · IRAKLIA | Fase 3 | En marcha, sin reclutar | nov 2024 (real) |
Todos los de SNY, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT00816452), actualizada en nov 2010.